Levodopa therapy for Parkinson's disease: Challenges and future prospects
Identifieur interne : 004146 ( Istex/Corpus ); précédent : 004145; suivant : 004147Levodopa therapy for Parkinson's disease: Challenges and future prospects
Auteurs : C. Warren Olanow ; Andrew Lees ; Jose ObesoSource :
- Movement Disorders [ 0885-3185 ] ; 2008.
Url:
DOI: 10.1002/mds.22048
Links to Exploration step
ISTEX:D35841F7896897E9A53380B2789DC94ED82E0793Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa therapy for Parkinson's disease: Challenges and future prospects</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Neurology, Reta Lila Institute of Neurological Studies, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Obeso, Jose" sort="Obeso, Jose" uniqKey="Obeso J" first="Jose" last="Obeso">Jose Obeso</name><affiliation><mods:affiliation>Department of Neurology, University of Navarra, Pamplona, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D35841F7896897E9A53380B2789DC94ED82E0793</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22048</idno><idno type="url">https://api.istex.fr/document/D35841F7896897E9A53380B2789DC94ED82E0793/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004146</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa therapy for Parkinson's disease: Challenges and future prospects</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation><mods:affiliation>Department of Neurology, Reta Lila Institute of Neurological Studies, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Obeso, Jose" sort="Obeso, Jose" uniqKey="Obeso J" first="Jose" last="Obeso">Jose Obeso</name><affiliation><mods:affiliation>Department of Neurology, University of Navarra, Pamplona, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S495">S495</biblScope><biblScope unit="page" to="S496">S496</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D35841F7896897E9A53380B2789DC94ED82E0793</idno><idno type="DOI">10.1002/mds.22048</idno><idno type="ArticleID">MDS22048</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>C. Warren Olanow MD</name><affiliations><json:string>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Andrew Lees MD</name><affiliations><json:string>Department of Neurology, Reta Lila Institute of Neurological Studies, London, UK</json:string></affiliations></json:item><json:item><name>Jose Obeso MD</name><affiliations><json:string>Department of Neurology, University of Navarra, Pamplona, Spain</json:string></affiliations></json:item></author><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>2</total><last>S496</last><first>S495</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S3</issue><subject><json:item><value>Introduction</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><language><json:string>eng</json:string></language><qualityIndicators><score>1.008</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>0</abstractCharCount><pdfWordCount>958</pdfWordCount><pdfCharCount>6247</pdfCharCount><pdfPageCount>2</pdfPageCount><abstractWordCount>0</abstractWordCount></qualityIndicators><title>Levodopa therapy for Parkinson's disease: Challenges and future prospects</title><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.22048</json:string></doi><id>D35841F7896897E9A53380B2789DC94ED82E0793</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/D35841F7896897E9A53380B2789DC94ED82E0793/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/D35841F7896897E9A53380B2789DC94ED82E0793/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/D35841F7896897E9A53380B2789DC94ED82E0793/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Levodopa therapy for Parkinson's disease: Challenges and future prospects</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Dr. Olanow has served as a consultant for Novartis, Teva, BI, Solvay, Ceregene, and Merck Second.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Levodopa therapy for Parkinson's disease: Challenges and future prospects</title><author><persName><forename type="first">C. Warren</forename><surname>Olanow</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Annenberg 1494, New York</p></note><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</affiliation></author><author><persName><forename type="first">Andrew</forename><surname>Lees</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Reta Lila Institute of Neurological Studies, London, UK</affiliation></author><author><persName><forename type="first">Jose</forename><surname>Obeso</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Navarra, Pamplona, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S495">S495</biblScope><biblScope unit="page" to="S496">S496</biblScope></imprint></monogr><idno type="istex">D35841F7896897E9A53380B2789DC94ED82E0793</idno><idno type="DOI">10.1002/mds.22048</idno><idno type="ArticleID">MDS22048</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Introduction</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-01-28">Received</change><change when="2008-03-02">Registration</change><change when="2008">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/D35841F7896897E9A53380B2789DC94ED82E0793/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="115"><doi origin="wiley" registered="yes">10.1002/mds.v23:3+</doi><titleGroup><title type="supplementTitle">Levodopa Treatment and Motor Complications in Parkinson's Disease: Scientific Basis and Therapeutic Approaches‐ Guest Editors Dr. C. Warren Olanow, Dr. Andrew Lees, and Dr. Jose Obeso</title></titleGroup><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">S3</numbering><numbering type="supplement" number="S3">S3</numbering></numberingGroup><coverDate startDate="2008">2008</coverDate></publicationMeta><publicationMeta level="unit" type="editorial" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22048</doi><idGroup><id type="unit" value="MDS22048"></id></idGroup><countGroup><count type="pageTotal" number="2"></count></countGroup><titleGroup><title type="articleCategory">Introduction</title><title type="tocHeading1">Introduction</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-01-28"></event><event type="manuscriptAccepted" date="2008-03-02"></event><event type="firstOnline" date="2008-09-09"></event><event type="publishedOnlineFinalForm" date="2008-09-09"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">S495</numbering><numbering type="pageLast">S496</numbering></numberingGroup><correspondenceTo>Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Annenberg 1494, New York</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22048.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="6"></count><count type="wordTotal" number="998"></count></countGroup><titleGroup><title type="main" xml:lang="en">Levodopa therapy for Parkinson's disease: Challenges and future prospects<link href="#fn1"></link></title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>C. Warren</givenNames><familyName>Olanow</familyName><degrees>MD</degrees></personName><contactDetails><email>warren.olanow@mssm.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Andrew</givenNames><familyName>Lees</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Jose</givenNames><familyName>Obeso</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neurology, Reta Lila Institute of Neurological Studies, London, UK</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="ES" type="organization"><unparsedAffiliation>Department of Neurology, University of Navarra, Pamplona, Spain</unparsedAffiliation></affiliation></affiliationGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Dr. Olanow has served as a consultant for Novartis, Teva, BI, Solvay, Ceregene, and Merck Second.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Levodopa therapy for Parkinson's disease: Challenges and future prospects</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Levodopa therapy for Parkinson's disease: Challenges and future prospects</title></titleInfo><name type="personal"><namePart type="given">C. Warren</namePart><namePart type="family">Olanow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA</affiliation><description>Correspondence: Department of Neurology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Annenberg 1494, New York</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Lees</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Reta Lila Institute of Neurological Studies, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jose</namePart><namePart type="family">Obeso</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Navarra, Pamplona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">editorial</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008</dateIssued><dateCaptured encoding="w3cdtf">2008-01-28</dateCaptured><dateValid encoding="w3cdtf">2008-03-02</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">6</extent><extent unit="words">998</extent></physicalDescription><note type="content">*Potential conflict of interest: Dr. Olanow has served as a consultant for Novartis, Teva, BI, Solvay, Ceregene, and Merck Second.</note><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Introduction</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>S3</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>S3</number></detail><extent unit="pages"><start>S495</start><end>S496</end><total>2</total></extent></part></relatedItem><identifier type="istex">D35841F7896897E9A53380B2789DC94ED82E0793</identifier><identifier type="DOI">10.1002/mds.22048</identifier><identifier type="ArticleID">MDS22048</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004146 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 004146 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D35841F7896897E9A53380B2789DC94ED82E0793
|texte= Levodopa therapy for Parkinson's disease: Challenges and future prospects
}}
| This area was generated with Dilib version V0.6.23. |  |